Symbols / CADL
CADL Chart
About
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 279.43M |
| Enterprise Value | 199.68M | Income | -22.76M | Sales | — |
| Book/sh | 1.46 | Cash/sh | 1.58 | Dividend Yield | — |
| Payout | 0.00% | Employees | 38 | IPO | — |
| P/E | — | Forward P/E | -8.48 | PEG | — |
| P/S | — | P/B | 3.49 | P/C | — |
| EV/EBITDA | -5.13 | EV/Sales | — | Quick Ratio | 7.96 |
| Current Ratio | 8.25 | Debt/Eq | 8.99 | LT Debt/Eq | — |
| EPS (ttm) | -0.56 | EPS next Y | -0.60 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-12 | ROA | -43.25% |
| ROE | -70.17% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 54.90M |
| Shs Float | 47.86M | Short Float | 21.52% | Short Ratio | 12.89 |
| Short Interest | — | 52W High | 12.02 | 52W Low | 4.25 |
| Beta | -0.93 | Avg Volume | 905.50K | Volume | 2.86M |
| Target Price | $18.62 | Recom | Strong_buy | Prev Close | $4.97 |
| Price | $5.09 | Change | 2.41% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$18.63
Mean price target
2. Current target
$5.09
Latest analyst target
3. DCF / Fair value
$-6.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.09
Low
$7.00
High
$25.00
Mean
$18.63
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-08 | reit | Stephens & Co. | Overweight → Overweight | $15 |
| 2025-11-14 | main | Citigroup | Buy → Buy | $24 |
| 2025-10-28 | init | Stephens & Co. | — → Overweight | $15 |
| 2025-10-21 | init | LifeSci Capital | — → Outperform | $16 |
| 2025-09-29 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-09-03 | down | B of A Securities | Buy → Neutral | $7 |
| 2025-04-11 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-03-14 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-02-26 | main | Canaccord Genuity | Buy → Buy | $25 |
| 2025-02-26 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-02-20 | init | Citigroup | — → Buy | $25 |
| 2025-02-19 | init | Canaccord Genuity | — → Buy | $20 |
| 2025-02-07 | init | B of A Securities | — → Buy | $15 |
| 2024-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2024-11-18 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-05-22 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-05-15 | main | BMO Capital | Outperform → Outperform | $3 |
| 2023-03-31 | main | Credit Suisse | — → Outperform | $7 |
| 2022-12-07 | main | Credit Suisse | — → Outperform | $8 |
- Cancer biotech Candel prices $100M sale to back prostate launch prep, lung trial - Stock Titan Fri, 20 Feb 2026 06
- Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits Fri, 20 Feb 2026 01
- Candel Therapeutics Prices $100 Mln Shares Offering At $5.45/shr To Advance Aglatimagene;Stock Down - Nasdaq Fri, 20 Feb 2026 08
- Candel Therapeutics, Inc. (CADL) Stock Analysis: Biotech's Potential 218% Upside Sparks Investor Interest - DirectorsTalk Interviews Fri, 20 Feb 2026 05
- Candel Therapeutics Announces Equity Offering to Fund CAN-2409 - TipRanks Mon, 23 Feb 2026 14
- Why CADL stock plunged nearly 15% in after-hours trading today - MSN Wed, 25 Feb 2026 00
- Candel Therapeutics stock falls on $100 million offering pricing - Investing.com Fri, 20 Feb 2026 14
- Candel Therapeutics Prices 18.35M-Share Offering at $5.45, Expects ~$93.5M Net Proceeds - TradingView Mon, 23 Feb 2026 13
- Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL) - simplywall.st Sat, 17 Jan 2026 08
- The Technical Signals Behind (CADL) That Institutions Follow - Stock Traders Daily Fri, 20 Feb 2026 02
- Candel Therapeutics Prices $100 Million Share Offering - Intellectia AI Sat, 21 Feb 2026 14
- Cancer-drug maker Candel plans $100M sale for prostate, lung push - Stock Titan hu, 19 Feb 2026 21
- Candel Therapeutics Faces Strategic Financial Moves Amidst Stock Offering - timothysykes.com Sun, 22 Feb 2026 13
- Candel Therapeutics prices $100M public offering - Proactive financial news Fri, 20 Feb 2026 08
- Aug Decliners: Whats the RSI of CADL stock - Market Volume Summary & Advanced Swing Trade Entry Plans - baoquankhu1.vn Wed, 25 Feb 2026 02
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 937 | 6540 | — | Sale at price 6.98 per share. | NICHOLS WILLIAMS GARRETT | Officer | — | 2025-07-28 00:00:00 | D |
| 1 | 937 | 1209 | — | Conversion of Exercise of derivative security at price 1.29 per share. | NICHOLS WILLIAMS GARRETT | Officer | — | 2025-07-28 00:00:00 | D |
| 2 | 781 | 3936 | — | Sale at price 5.04 per share. | NICHOLS WILLIAMS GARRETT | Officer | — | 2025-06-30 00:00:00 | D |
| 3 | 781 | 1007 | — | Conversion of Exercise of derivative security at price 1.29 per share. | NICHOLS WILLIAMS GARRETT | Officer | — | 2025-06-30 00:00:00 | D |
| 4 | 64239 | 299996 | — | Stock Award(Grant) at price 4.67 per share. | PAPA JOSEPH C | Director | — | 2025-06-25 00:00:00 | I |
| 5 | 1070663 | 4999996 | — | Stock Award(Grant) at price 4.67 per share. | MANNING PAUL B. | Director | — | 2025-06-25 00:00:00 | I |
| 6 | 5353 | 24999 | — | Stock Award(Grant) at price 4.67 per share. | NABEL GARY J. | Director | — | 2025-06-25 00:00:00 | D |
| 7 | 111349 | 520000 | — | Stock Award(Grant) at price 4.67 per share. | MARTELL CHRISTOPHER | Director | — | 2025-06-25 00:00:00 | I |
| 8 | 42826 | 199997 | — | Stock Award(Grant) at price 4.67 per share. | TAK PAUL PETER | Chief Executive Officer | — | 2025-06-25 00:00:00 | D |
| 9 | 4282 | 19997 | — | Stock Award(Grant) at price 4.67 per share. | BARONE FRANCESCA | Officer | — | 2025-06-25 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -31.30M | -35.35M | -32.68M | -13.00M |
| TotalUnusualItems | -20.80M | 966.00K | 16.37M | -11.42M |
| TotalUnusualItemsExcludingGoodwill | -20.80M | 966.00K | 16.37M | -11.42M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -55.18M | -37.94M | -18.79M | -36.12M |
| ReconciledDepreciation | 990.00K | 960.00K | 778.00K | 232.00K |
| EBITDA | -52.10M | -34.38M | -16.31M | -24.42M |
| EBIT | -53.09M | -35.34M | -17.09M | -24.65M |
| NetInterestIncome | -1.00M | -514.00K | -490.00K | -53.00K |
| InterestExpense | 2.09M | 2.60M | 1.71M | 53.00K |
| InterestIncome | 1.09M | 2.08M | 1.22M | |
| NormalizedIncome | -34.38M | -38.91M | -35.16M | -24.70M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -55.18M | -37.94M | -18.79M | -36.12M |
| TotalExpenses | 33.37M | 38.39M | 34.80M | 24.77M |
| RentExpenseSupplemental | 192.00K | 161.00K | 184.00K | 250.00K |
| TotalOperatingIncomeAsReported | -33.37M | -38.39M | -34.72M | -25.73M |
| DilutedAverageShares | 31.68M | 28.94M | 28.82M | 18.87M |
| BasicAverageShares | 31.68M | 28.94M | 28.82M | 18.87M |
| DilutedEPS | -1.74 | -1.31 | -0.65 | -1.91 |
| BasicEPS | -1.74 | -1.31 | -0.65 | -1.91 |
| DilutedNIAvailtoComStockholders | -55.18M | -37.94M | -18.79M | -36.12M |
| NetIncomeCommonStockholders | -55.18M | -37.94M | -18.79M | -36.12M |
| NetIncome | -55.18M | -37.94M | -18.79M | -36.12M |
| NetIncomeIncludingNoncontrollingInterests | -55.18M | -37.94M | -18.79M | -36.12M |
| NetIncomeContinuousOperations | -55.18M | -37.94M | -18.79M | -36.12M |
| PretaxIncome | -55.18M | -37.94M | -18.79M | -36.12M |
| OtherIncomeExpense | -20.80M | 966.00K | 16.37M | -11.42M |
| GainOnSaleOfSecurity | -20.80M | 966.00K | 16.37M | -11.42M |
| NetNonOperatingInterestIncomeExpense | -1.00M | -514.00K | -490.00K | -53.00K |
| TotalOtherFinanceCost | 490.00K | 53.00K | ||
| InterestExpenseNonOperating | 2.09M | 2.60M | 1.71M | 53.00K |
| InterestIncomeNonOperating | 1.09M | 2.08M | 1.22M | |
| OperatingIncome | -33.37M | -38.39M | -34.67M | -24.65M |
| OperatingExpense | 33.37M | 38.39M | 34.80M | 24.77M |
| OtherOperatingExpenses | -48.00K | -1.08M | ||
| ResearchAndDevelopment | 19.31M | 24.51M | 20.79M | 15.18M |
| SellingGeneralAndAdministration | 14.06M | 13.88M | 14.06M | 10.67M |
| GeneralAndAdministrativeExpense | 14.06M | 13.88M | 14.06M | 10.67M |
| OtherGandA | 5.85M | 4.39M | 4.26M | 3.55M |
| InsuranceAndClaims | 1.19M | 1.60M | 2.38M | 1.18M |
| RentAndLandingFees | 192.00K | 161.00K | 184.00K | 250.00K |
| SalariesAndWages | 6.83M | 7.73M | 7.23M | 5.69M |
| TotalRevenue | 0.00 | 0.00 | 125.00K | 125.00K |
| OperatingRevenue | 0.00 | 0.00 | 125.00K | 125.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 122.61K | 122.61K | 122.61K | |
| OrdinarySharesNumber | 46.81M | 29.09M | 28.92M | 28.69M |
| ShareIssued | 46.93M | 29.21M | 29.04M | 28.69M |
| TotalDebt | 13.47M | 22.76M | 22.80M | 560.00K |
| TangibleBookValue | 66.33M | 12.74M | 47.71M | 64.14M |
| InvestedCapital | 78.83M | 34.02M | 68.56M | 64.70M |
| WorkingCapital | 66.28M | 22.61M | 66.33M | 79.58M |
| NetTangibleAssets | 66.33M | 12.74M | 47.71M | 64.14M |
| CapitalLeaseObligations | 973.00K | 1.49M | 1.95M | 0.00 |
| CommonStockEquity | 66.33M | 12.74M | 47.71M | 64.14M |
| TotalCapitalization | 68.93M | 25.13M | 68.56M | 64.70M |
| TotalEquityGrossMinorityInterest | 66.33M | 12.74M | 47.71M | 64.14M |
| StockholdersEquity | 66.33M | 12.74M | 47.71M | 64.14M |
| TreasuryStock | 448.00K | 448.00K | 448.00K | 0.00 |
| RetainedEarnings | -192.21M | -137.03M | -99.09M | -80.30M |
| AdditionalPaidInCapital | 258.51M | 149.93M | 146.96M | 144.15M |
| CapitalStock | 469.00K | 290.00K | 290.00K | 286.00K |
| CommonStock | 469.00K | 290.00K | 290.00K | 286.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 40.54M | 28.46M | 29.98M | 25.07M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.01M | 14.27M | 24.36M | 19.71M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| DerivativeProductLiabilities | 0.00 | 916.00K | 1.88M | 18.25M |
| NonCurrentDeferredLiabilities | 0.00 | 144.00K | 894.00K | |
| NonCurrentDeferredRevenue | 0.00 | 144.00K | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 3.01M | 13.36M | 22.34M | 560.00K |
| LongTermCapitalLeaseObligation | 407.00K | 973.00K | 1.49M | 0.00 |
| LongTermDebt | 2.60M | 12.38M | 20.85M | 560.00K |
| CurrentLiabilities | 37.53M | 14.18M | 5.62M | 5.36M |
| OtherCurrentLiabilities | 21.72M | 48.00K | 334.00K | |
| CurrentDebtAndCapitalLeaseObligation | 10.46M | 9.41M | 464.00K | |
| CurrentCapitalLeaseObligation | 566.00K | 513.00K | 464.00K | 0.00 |
| CurrentDebt | 9.89M | 8.89M | ||
| OtherCurrentBorrowings | 9.89M | 8.89M | ||
| LineOfCredit | 0.00 | |||
| PayablesAndAccruedExpenses | 5.35M | 4.78M | 5.10M | 5.03M |
| CurrentAccruedExpenses | 5.11M | 4.36M | 4.72M | 3.44M |
| Payables | 237.00K | 422.00K | 380.00K | 1.59M |
| AccountsPayable | 237.00K | 422.00K | 380.00K | 1.59M |
| TotalAssets | 106.87M | 41.20M | 77.69M | 89.20M |
| TotalNonCurrentAssets | 3.06M | 4.40M | 5.75M | 4.26M |
| OtherNonCurrentAssets | 329.00K | 382.00K | 266.00K | 424.00K |
| NetPPE | 2.73M | 4.02M | 5.48M | 3.84M |
| AccumulatedDepreciation | -3.08M | -2.09M | -1.13M | -352.00K |
| GrossPPE | 5.81M | 6.11M | 6.61M | 4.19M |
| Leases | 3.11M | 3.11M | 3.06M | 2.99M |
| ConstructionInProgress | 0.00 | |||
| OtherProperties | 2.46M | 2.75M | 3.31M | 1.01M |
| MachineryFurnitureEquipment | 244.00K | 247.00K | 240.00K | 184.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 103.80M | 36.80M | 71.94M | 84.94M |
| OtherCurrentAssets | 1.15M | 1.38M | 1.89M | 2.30M |
| PrepaidAssets | 2.30M | |||
| CashCashEquivalentsAndShortTermInvestments | 102.65M | 35.41M | 70.06M | 82.64M |
| CashAndCashEquivalents | 102.65M | 35.41M | 70.06M | 82.64M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -27.04M | -34.70M | -32.72M | -24.05M |
| RepaymentOfDebt | -9.17M | 0.00 | ||
| IssuanceOfDebt | 0.00 | 19.91M | 0.00 | |
| IssuanceOfCapitalStock | 101.76M | 0.00 | 0.00 | 71.33M |
| CapitalExpenditure | -16.00K | -457.00K | -1.30M | -1.83M |
| InterestPaidSupplementalData | 1.79M | 2.15M | 1.15M | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 183.00K | 29.00K | |
| EndCashPosition | 102.92M | 35.68M | 70.32M | 83.07M |
| BeginningCashPosition | 35.68M | 70.32M | 83.07M | 35.32M |
| ChangesInCash | 67.24M | -34.65M | -12.74M | 47.75M |
| FinancingCashFlow | 94.28M | -121.00K | 19.97M | 71.80M |
| CashFlowFromContinuingFinancingActivities | 94.28M | -121.00K | 19.97M | 71.80M |
| NetOtherFinancingCharges | -121.00K | |||
| ProceedsFromStockOptionExercised | 1.69M | 0.00 | 64.00K | 465.00K |
| NetCommonStockIssuance | 101.76M | 0.00 | 0.00 | 71.33M |
| CommonStockIssuance | 101.76M | 0.00 | 0.00 | 71.33M |
| NetIssuancePaymentsOfDebt | -9.17M | 0.00 | 19.91M | 0.00 |
| NetLongTermDebtIssuance | -9.17M | 0.00 | 19.91M | 0.00 |
| LongTermDebtPayments | -9.17M | 0.00 | ||
| LongTermDebtIssuance | 0.00 | 19.91M | 0.00 | |
| InvestingCashFlow | -16.00K | -280.00K | -1.30M | -1.83M |
| CashFlowFromContinuingInvestingActivities | -16.00K | -280.00K | -1.30M | -1.83M |
| NetInvestmentPurchaseAndSale | 0.00 | |||
| SaleOfInvestment | 0.00 | |||
| PurchaseOfInvestment | 0.00 | |||
| NetPPEPurchaseAndSale | -16.00K | -280.00K | -1.30M | -1.83M |
| SaleOfPPE | 0.00 | 177.00K | 0.00 | |
| PurchaseOfPPE | -16.00K | -457.00K | -1.30M | -1.83M |
| OperatingCashFlow | -27.02M | -34.24M | -31.42M | -22.22M |
| CashFlowFromContinuingOperatingActivities | -27.02M | -34.24M | -31.42M | -22.22M |
| ChangeInWorkingCapital | 346.00K | -525.00K | 71.00K | -876.00K |
| ChangeInOtherWorkingCapital | -192.00K | 67.00K | 285.00K | |
| ChangeInOtherCurrentLiabilities | -513.00K | -464.00K | -464.00K | 0.00 |
| ChangeInOtherCurrentAssets | 53.00K | -116.00K | 0.00 | 83.00K |
| ChangeInPayablesAndAccruedExpense | 572.00K | -256.00K | 52.00K | 966.00K |
| ChangeInAccruedExpense | 757.00K | -301.00K | 1.26M | 297.00K |
| ChangeInPayable | -185.00K | 45.00K | -1.21M | 669.00K |
| ChangeInAccountPayable | -185.00K | 45.00K | -1.21M | 669.00K |
| ChangeInPrepaidAssets | 234.00K | 503.00K | 416.00K | -2.21M |
| OtherNonCashItems | 663.00K | 666.00K | 589.00K | 76.00K |
| StockBasedCompensation | 5.31M | 3.09M | 2.31M | 2.96M |
| AssetImpairmentCharge | 41.00K | 390.00K | 0.00 | 553.00K |
| DepreciationAmortizationDepletion | 990.00K | 960.00K | 778.00K | 232.00K |
| DepreciationAndAmortization | 990.00K | 960.00K | 778.00K | 232.00K |
| Depreciation | 990.00K | 960.00K | 778.00K | 232.00K |
| OperatingGainsLosses | 20.80M | -887.00K | -16.37M | 10.96M |
| GainLossOnInvestmentSecurities | 20.80M | -966.00K | -16.37M | 11.42M |
| GainLossOnSaleOfPPE | 0.00 | 79.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -55.18M | -37.94M | -18.79M | -36.12M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CADL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|